Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced a definitive securities purchase agreement for an At-the-Market private placement, raising gross proceeds of approximately $1.425 million. The agreement involves the issuance of 136,844 shares of common stock and 93,179 pre-funded warrants, alongside warrants to purchase additional shares at specified prices. The funds will support the announcement of clinical data from Artelo's phase 1 and phase 2 studies, with a portion allocated to purchasing the digital currency SOL and for general corporate purposes. The closing of the offering is contingent upon customary conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.